A Phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer

Cancer Investigation

Volumn 22, Issue 3, 2004, Pages 374-382

  Friedland, David M ^a,b   Dakhil, Shaker ^a   Hollen, Charles ^a   Gregurich, Mary Ann ^a   Asmar, Linar ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Advanced urothelial carcinoma; Carboplatin; Paclitaxel

Indexed keywords

AMIFOSTINE; BCG VACCINE; CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; INTERFERON; INTERLEUKIN 2; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; MALE; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SEPSIS; STOMATITIS; SURVIVAL TIME; THROMBOEMBOLISM; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CARBOPLATIN; CARCINOMA; COMBINED MODALITY THERAPY; DEXAMETHASONE; DIPHENHYDRAMINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYPERGLYCEMIA; LIFE TABLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PREMEDICATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 4744376269     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200029064     Document Type: Conference Paper

References (23)

1. American Cancer Society. What are the Key Statistics for Bladder Cancer? http://www.cancer.org, accessed July 05, 2002.
2. Greenlee, R.T.; Murray, T.; Bolden, S.; Wingo, P.A. Cancer statistics, 2000. CA. Can. J. Clin. 2000, 50 (1), 7-33.
3. Sternberg, C.N.; Yagoda, A.; Scher, H.I.; Watson, R.C.; Geller, N.; Herr, H.W.; Morse, M.J.; Sogani, P.C.; Vaughan, E.D.; Bander, N. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989, 64 (12), 2448-2458.
4. Logothetis, C.J.; Dexeus, F.; Finn, L.; Sella, A.; Amato, R.J.; Ayala, A.G.; Kilbourn, R.G. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors. J. Clin. Oncol. 1990, 8 (6), 1050-1055.
5. Loehrer, P.J., Sr.; Einhorn, L.H.; Elson, P.J.; Crawford, E.D.; Kuebler, P.; Tannock, I.; Raghavan, D.; Stuart-Harris, R.; Sarosdy, M.F.; Lowe, B.A. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992, 10 (7), 1066-1073.
6. Von der Maase, H.; Hansen, S.W.; Roberts, J.T.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Bodrogi, I.; Albers, P.; Knuth, A.; Lippert, C.M.; Kerbrat, P.; Sanchez Rovira, P.; Wersall, P.; Cleall, S.P.; Roychowdhury, D.F.; Tomlin, I.; Visseren-Grul, C.M.; Conte, P.F. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter phase III study. J. Clin. Oncol. 2000, 18 (17), 3068-3077.
7. Roth, B.J.; Dreicer, R.; Einhorn, L.E.; Neuberg, D.; Johnson, D.H.; Smith, J.L.; Hudes, G.R.; Schultz, S.M.; Loehrer, P.J. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 1994, 12 (11), 2264-2270.
8. Dreicer, R.; Manola, J.; Roth, B.J.; Cohen, M.B.; Hatfield, A.K.; Wilding, G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2000, 18 (5), 1058-1061.
9. Tu, S.M.; Hossan, E.; Amato, R.; Kilbourn, R.; Logothetis, C.J. Paclitaxel, cisplatin, and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J. Urol. 1995, 154 (5), 1719-1722.
10. Bajorin, D.F.; McCaffrey, J.A.; Dodd, P.M.; Hilton, S.; Mazumdar, M.; Kelly, W.K.; Herr, H.; Scher, H.I.; Icasiano, E.; Higgins, G. Ifosfamide, Paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000, 88 (7), 1671-1678.
11. Langer, C.J.; Leighton, J.C.; Comis, R.L.; O'Dwyer, J.P.; McAleer, C.A.; Bonjo, C.A.; Engstron, P.F.; Lifein, S.; Ozols, R.F. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: phase II toxicity, response, and survival analysis. J. Clin. Oncol. 1995, 13 (8), 1860-1870.
12. Natale, R.B. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 1996, 23 (5 suppl 12), 2-6.
13. Vaughn, D.J.; Malkowicz, S.B.; Zoltick, B.; Mick, R.; Ramchandani, P.; Holroyde, C.; Armstead, B.; Fox, K.; Wein, A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J. Clin. Oncol. 1998, 16 (1), 255-260.
14. Redman, E.G.; Smith, D.C.; Flaherty, L.; Du, W.; Hussain, M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J. Clin. Oncol. 1998, 16 (5), 1844-1848.
15. Small, E.J.; Lew, D.; Redman, E.G.; Petrylak, O.P.; Hammond, N.; Gross, H.M.; Eastham, J.A.; Crawford, E.D. Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J. Clin. Oncol. 2000, 18 (13), 2537-2544.
16. Ukena, D.; Leutz, M.; Schroder, R.; Sybrecht, G.W. Intensified treatment of stage IV non-small cell lung cancer (NSCLC): weekly chemotherapy with paclitaxel and carboplatin. Lung Cancer 1997, 18 (1), 34 (Abstract 122).
17. Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989, 10 (1), 1-10.
18. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53 (282), 457-481.
19. Meluch, A.A.; Burris, H.S.; Greco, P.A.; Hainsworth, J.D. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. Eur. J. Cancer 2000, 36 (suppl 2), 30-33.
20. Bajorin, D.F.; Dodd, P.M.; Mazumdar, M.; Fazzari, M.; McCaffrey, J.A.; Scher, H.I.; Herr, H.; Higgins, G.; Boyle, M.G. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 1999, 17 (10), 3173-3181.
21. Dodd, P.M.; McCaffrey, J.A.; Hilton, S.; Mazumdar, M.; Herr, H.; Kelly, W.K.; Icasiano, E.; Boyle, M.G.; Bajorin, D.F. Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J. Clin. Oncol. 2000, 18 (4), 840-846.
22. Witte, R.S.; Elson, P.; Bono, B.; Knop, R.; Richardson, R.R.; Dreicer, R.; Locher, P.J. Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J. Clin. Oncol. 1997, 15 (2), 589-593.
23. Lorusso, V.; Pollera, C.F.; Antimi, M.; Luporini, G.; Gridelli, C.; Frassinetti, G.L.; Oliva, C.; Pacini, M.; DeLena, M. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur. J Cancer 1998, 34 (8), 1208-1212.